Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo …
WEB15 hours ago — On Friday, Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY) for $825 million as an upfront payment and additional ...
In sustained rare disease push, Recordati lays out $825M upfront …
WEB16 hours ago — Recordati is floating $825 million upfront—plus another $250 million in potential commercial milestones—to get its hands on the global rights to Sanofi’s rare disease biologic Enjaymo.
Sanofi Drug for Rare Blood Disease Is Heading to Recordati for …
WEB1 day ago — Enjaymo generated €72 million (about $79 million) in sales last year, a 240% increase over the product’s sales in 2022, according to Sanofi’s annual report. Sales for Enjaymo are continuing ...
Sanofi’s rare disease drug finds yet another home
WEB14 hours ago — By 2017, it had been snapped up by Biogen’s hemophilia-focused spin off Bioverativ. John Cox, the then-CEO of Bioverativ, said at the time that Enjaymo was a central asset in the deal and filled an important gap in the company’s research efforts. Enjaymo, however, would move to yet another owner in 2018, when Sanofi bought Bioverativ for ...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO ...
WEB1 day ago — Milan, 4th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for ...
Recordati to Buy Global Rights to Sanofi's Enjaymo for $825 Million
WEB23 hours ago — Global News Select Recordati to Buy Global Rights to Sanofi's Enjaymo for $825 Million Provided by ... Enjaymo's revenue amounted to around 100 million euros ($110.3 million) for the 12 months to ...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO ...
WEB1 day ago — Recordati will host a conference call today, 4 th October, at 13:00 CEST (12:00 p.m. GMT) to discuss the agreement to acquire Enjaymo®.The dial-in numbers for the conference call service are ...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO ...
WEB1 day ago — Milan, 4 th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.. Enjaymo® (sutimlimab) is a humanized monoclonal antibody indicated for the treatment of hemolysis in adults ...
Press Room - Sanofi US News
WEBJan 25, 2023 — The US Food and Drug Administration (FDA) has approved the expanded indication for Enjaymo ® (sutimlimab-jome), the first and only treatment of hemolysis in adults with cold agglutinin disease (CAD), to include patients with or …
FDA Approves Enjaymo® after pivotal study results | Sanofi
WEBFeb 4, 2022 — FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease. Enjaymo is the only approved treatment to decrease the need for red blood cell transfusion due to hemolysis, the destruction of red blood cells, in adults with cold agglutinin disease (CAD)
- Some results have been removed